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8.1 Neurotrophism and Neurotrophic Factors
Neurotrophic factors (NTFs) are small natural proteins necessary for the
development and survival of nerve cells as well as for the maintenance of their
morphological and functional phenotype. The ‘neurotrophic hypothesis’
enunciates that the establishment and maintenance of neuronal networks
require the release at the target structures of NTFs, which are taken up by the
nerve terminals and retrogradely transported to the soma of the projecting
neurons. On reaching the nucleus, NTFs induce a gene programme that
promotes neuronal survival and maintenance of phenotype.
Although the existence of ‘chemotactic’ inﬂuences between the growth cones
of axons and their targets had already been postulated by Cajal’s group,1 the
modern concept of neurotrophism is based on the work of Hamburguer and
Levi-Montalcini2 who reported that the phenomenon of naturally occurring
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cell death observed during development was dependent on the target where
these dying neurons were projecting. Removing a prospective target early in
development could dramatically increase neuronal loss. In the absence of
target, the number of initially existing neurons did not change, indicating that
the target inﬂuences survival and not the number of neurons generated. These
seminal observations suggested that cells acting as a target of developing
neurons produce limited amount of speciﬁc molecules which are required for
their survival. The ﬁrst molecule identiﬁed with these speciﬁc characteristics
was the nerve growth factor (NGF).3,4 As indicated above, the current concept
of NTF applies not only to molecules regulating neuronal number during
development but also to agents necessary for the maintenance of neuronal
populations in adulthood.5,6
During the last decades, several proteins have been classiﬁed as NTFs
because their eﬀect on neuronal survival, diﬀerentiation (including synapto-
genesis and neurite branching in vitro), maturation of electrophysiological
properties, and plasticity. However, the role of these molecules as ‘canonical’
NTFs is not always well demonstrated. This is true even in the case of NGF
(the ‘prototypical NTF’), which is essential for the survival of sympathetic,
sensory and central cholinergic neurons. Nevertheless, the dependence of these
neuronal populations on NGF is not always conserved by the end of the
developmental critical period. Indeed, some postnatal neurons (as it is the case
of a subset of DRG neurons) can switch dependence from one (NGF) to
another (glial cell line-derived neurotrophic factor) trophic factor.7,8 Moreover,
although deprivation of NGF in the adult compromises sympathetic neurons
viability, it only aﬀects gene expression in sensory neurons without decreasing
their cell number.9 However, it has not been deﬁnitely established whether, in
the adult nervous system, neurons depend on one or several trophic factors
with overlapping eﬀects.
Because of their potent role in neuronal survival, NTFs have aroused clinical
interest as potential neuroprotective agents that could prevent or retard the
progression of neurodegenerative diseases. In this chapter we summarize cur-
rent knowledge on the role of NTFs in the pathogenesis of Parkinson’s disease
(PD), emphasizing the data obtained from animal models of NTF deﬁciency.
We also discuss the possible clinical applicability of NTFs as neuroprotective
agents in PD.
8.2 Neuroprotection of Mesencephalic Dopaminergic
Neurons: Role of GDNF
Parkinson’s disease (PD), a neurodegenerative disorder that aﬀects over one
million Europeans,10,11 is characterized by motor symptoms (tremor, brady-
kinesia, rigidity and alteration of gait).12,13 The aetiology and pathogenesis of
PD are essentially unknown, although several causative mechanisms have been
proposed including alterations of protein folding/degradation, mitochondrial
dysfunction andoxidative stress, neuroinﬂammation, andCa21 excitotoxicity.14,15
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PD is caused by the progressive loss of speciﬁc sets of neurons both in the brain-
stem and in the peripheral nervous system. From a clinical standpoint, the
most critical neuronal population aﬀected corresponds to the mesencephalic
dopaminergic (DA)neurons in the substantia nigra (SN) pars compacta projecting
to the striatum (nigrostriatal neurons), thus leading to dysfunction of the neuronal
circuits in the basal ganglia and alteration of motor control. DA neurons in
the neighbouring ventral tegmental area (VTA) are less aﬀected than SN neurons.
Although the loss of nigrostriatal DA neurons is the most apparent pathological
hallmark of PD, other cell types are aﬀected even before SN cell death. Among
those are noradrenergic neurons in the locus coeruleus (LC) and cells in the dorsal
nucleus of the vagus or in the sympathetic ganglia. Peripheral sympathetic
denervation (loss of cardiac or celiac ﬁbres) has been proposed to be an early
marker for PD.16
For the last decades, intrastriatal transplantation of dopamine-producing
cells (most frequently foetal mesencephalic DA neurons) has been considered as
an experimental therapeutic approach to advanced PD once pharmaceutical
drugs have ceased to provide clinical beneﬁt.17–19 However, allogenic cell
replacement therapies have recently been almost completely abandoned (for
discussion, see refs. 20,21) due to the scarcity of tissue available for trans-
plantation and because they do not always produce the expected beneﬁcial
eﬀects (and in some cases can even induce the appearance of abnormal
movements called dyskinesias22,23). Recently, intrastriatal delivery of NTFs,
which could ‘protect’ nigrostriatal neurons and thus halt or retard PD pro-
gression, is being considered as an alternative therapeutic strategy to dopamine
cell replacement.24 The prototypical ‘neuroprotective’ agent used in most
preclinical and clinical studies is glial cell line-derived neurotrophic factor
(GDNF), which after isolation demonstrated a remarkable trophic eﬀect on
mesencephalic DA neurons in vitro.25
8.2.1 Biology of GDNF and Other Dopaminotrophic Factors
GDNF belongs to a family of ligands, which include artemin (ARTN), neur-
turin (NRTN) and persephin (PSPN), all being distantly related members of the
transforming growth factor-beta superfamily. GDNF has attracted special
attention due to its potent eﬀect on dopaminergic and noradrenergic neuron
survival26,27 (see ref. 28 for a comprehensive review). Collectively, the members
of the GDNF family of trophic factors are often grouped as ‘dopaminotrophic’
factors. GDNF is expressed in several regions of the adult brain (particularly in
the striatum, anteroventral thalamus and septum)29,30 and signals through an
extracellular GPI-anchored receptor (GFRa1) that activates a tyrosine kinase
transmembrane protein (c-ret).26,31 A non-canonical form of GDNF signalling
also exists in the adult rodent brain, which is independent of Ret and is
mediated by neural cell adhesion molecule (NCAM).32AQ3 Like other NTFs,
GDNF is taken up by axon terminals of projecting neurons and transported
to cell soma (for a review on retrograde transport, see ref. 33). Injection of
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125I-GDNF in striatum results in labelled cells in the ipsilateral SN and VTA,
thus suggesting a trophic role of GNDF in adult nigrostriatal neurons.34
GDNF has been shown to activate pathways associated with the promotion
of antioxidant defence35 and neuronal survival.36 Among these pathways, the
PI3K/AKT cascade37 can protect neurons through several mechanisms including
inactivation of apoptotic proteins.38,39 GDNF overexpression (using lentiviral
infection or engineered GDNF-producing cells) protects catecholaminergic
neurons from toxic damage and induces ﬁbre outgrowth in vivo.26–27,40,41 How-
ever, the molecular mechanisms underlying these functional eﬀects are still
unknown. Recently, it has been reported that lentiviral GDNF delivered to the
rat striatum induces gene expression in the SN, notably tyrosine hydroxylase
(TH), GTP cyclohydrolase-I (which catalyses the synthesis of a cofactor of TH,
tetrahydrobiopterin), GDNF receptors, and Dlk-1 (a factor involved in cell
proliferation and diﬀerentiation). Since GDNF receptors are located in terminals
of SN neurons, it is expected that these genes are upregulated in DA SN neurons
in response to GDNF activation.42 In any event, GDNF-dependent signalling
pathways are as yet poorly studied and the role of GDNF in the maintenance
of adult DA neurons remains essentially unknown.
8.2.2 Dopaminotrophic Factor-Mediated Neuronal Protection
As indicated above, GDNF has a well-recognized potent neurotrophic eﬀect on
DA neurons in vitro. Addition of GDNF to primary cultures of midbrain
neurons favours the survival of the culture, and increases dopamine uptake, cell
size and neurite length.25 It has been demonstrated that GDNF exerts a
protective role on DA neurons exposed to neurotoxic agents.14 GDNF increases
the survival of mesencephalic DA neurons treated with either 1-methyl-4-
phenylpyridinium (MPP1) or 6-hydroxydopamine (6-OHDA) and promotes the
regrowth of damaged dopaminergic ﬁbres.43 A neuroprotective eﬀect of GDNF
against MPP1 toxicity has been also shown in organotypic cultures of ventral
mesencephalon, a preparation in which the integrity of DA neurons is better
preserved than in enzymatically dispersed preparations.44
As it occurs with GDNF, the other trophic factors members of the GDNF
family, NRTN, ARTN and PSPN, also increase the survival of DA neurons in
vitro and show a neuroprotective eﬀect on cells treated with 6-OHDA, although
they seem to be less eﬃcient than GDNF. The neuroprotective action of
NRNT45 and ARTN46 is mediated by cross-reactive stimulation of the cano-
nical GDNF receptor GFRa1-Ret that is expressed on DA neurons. Curiously,
PSPN was believed to be unable to stimulate the GFRa1-Ret receptor47 so the
mechanism by which it exerted the protective action on dopaminergic neurons
was uncertain. However, it has have been recently shown that PSPN can
activate the GFRa1-Ret receptor as well,48 explaining the protective eﬀect that
PSPN exerts on DA neurons.
Among the diﬀerent NTFs tested in vivo, GDNF has shown the most potent
and robust eﬀect on animal (rodent and primate) models of parkinsonism.28
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In the initial in vivo studies, the direct infusion of recombinant protein was used
to deliver GDNF to the brain parenchyma. These experiments demonstrated
that GDNF protects nigral DA neurons by activating their metabolism and
dopamine turnover. GDNF also induced axonal sprouting and striatal
reinnervation.49
As direct intrastriatal infusion of GDNF has potential complications derived
from the chronically implanted infusion device or the diﬀusion of the trophic
factor, an alternative approach for brain GDNF delivery is the administration
of replication-deﬁcient viral vectors. Three viral vector systems (adenovirus,
adeno-associated virus and lentivirus) engineered to produce continuous
expression of GDNF have been used with good experimental results.40,50,51 The
transfection based on adeno-associated virus and lentivirus is particularly
interesting because it produces a long-term expression of GDNF without
detectable cellular pathology or immune reaction (for a review, see ref. 28).
However, the use of viral vectors in patients raises safety concerns because of
their potential immunogenicity and the risk of mutagenesis by insertion into the
genome of host cells. Another strategy to produce continuous intrastriatal
GDNF delivery is the use of genetically modiﬁed cells that synthesize and
release GDNF. In this regard, several groups have reported protective eﬀects of
GDNF-secreting genetically modiﬁed cells in animal models of PD.52–55 The
long-term survival of the engineered cells and the prevention of the immune
reaction that they can trigger are two of the major hurdles that this technology
must overcome before it can be considered for clinical application.56
Intrastriatal grafting of carotid body (CB) cells is a methodology developed
in our laboratory that also seems to produce GDNF-mediated neuroprotection
in PD.57,58 The CB, a bilateral organ located in the bifurcation of the carotid
artery, is a major arterial chemoreceptor organ responsible for the detection of
changes in O2 concentration in the blood. In conditions presenting hypoxemia,
CB sensory cells release transmitters that activate aﬀerent sensory ﬁbres
terminating in the respiratory centre to induce a compensatory hyperventila-
tory response.59 CB sensory cells (called glomus cells) are of neural-crest origin
and contain high levels of dopamine as well as GDNF (Figure 8.1)60,61 and are
thus well-suited to be used as donor tissue in transplantation studies in PD.
Indeed, intrastriatal CB grafts can produce a signiﬁcant histological and
functional recovery in rodent and primate models of parkinsonism57–58,60
(Figure 8.2A). It has been shown that the beneﬁt induced by rat CB grafts is
mainly due to a trophic eﬀect on the nigrostriatal neurons rather than to the
release of dopamine from the transplanted cells.60 Once in the brain, grafted CB
cells remain metabolically active during the entire animal lifespan and maintain
their ability to produce GDNF (Figures 8.2B and 8.2C).61 The reason for the
long-lasting cell survival observed in CB transplants might be related to the fact
that glomus cells are activated by hypoxia, an environmental condition pre-
sumed to be present inside the graft that is possibly deleterious for other cells
types. Another advantage for the clinical application of CB cell therapy is that
it allows autografts to be performed in PD patients, since unilateral CB surgical
resection has no signiﬁcant side eﬀects in humans.62
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Two phase I/II clinical trials have shown that CB autotransplantation
induces clinical beneﬁts in PD patients, particularly in those who are not in an
advanced stage of the disease.63,64 The CB is small organ and therefore a
limitation of CB-based cell therapy is the scarcity of tissue available for
transplantation. To overcome this obstacle we have started a programme to
expand CB cells in vitro. It is well-known that, in conditions of chronic
hypoxemia (i.e. in high altitude residents or in patients with chronic obstructive
pulmonary diseases), the CB undergoes a compensatory hypertrophy.65–67 This
led us to hypothesize that adult mammalian CB could contain latent neural
progenitors activated by low O2 tension. In accord with this proposal, we have
Figure 8.1 Synthesis and release of GDNF in dopaminergic carotid body glomus
cells. (A) Histological section of mouse carotid body tissue showing the
expression of GDNF (green colour aggregasomes, X-gal staining) in
tyrosine hydroxylase (TH) positive glomus cells (brown colour). (B) and
(C) Measurement of GDNF content (B) and release to the medium (C) in
cultures of rat carotid body (CB), adrenal medulla (AM), organ of
Zuckerkandl (Zuck) and PC12 cells.AQ4 (D–I) Immunohistochemical analysis
showing that the GDNF promoter is active in mouse type I carotid body
cells (TH positive and glial ﬁbrillary acidic protein (GFAP) negative cells).
Modiﬁed from ref. 61. Animals GDNF/LacZ were used to study activity
of the GFAP promoter (see refs. 60,71).
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identiﬁed in the CB a population of neural crest-derived stem cells that in
response to hypoxia can proliferate and diﬀerentiate in new dopaminergic and
GDNF-producing glomus cells.68 We are currently investigating whether these
newly identiﬁed progenitors are active in humans and if they can be used to
expand CB tissue before transplantation.
8.3 Genetic Models of NTF Depletion: Conditional
GDNF Knock-out Mice
Most of the knowledge available on the physiological function of GDNF has
come from the analysis of genetically modiﬁed mice models. It is more than 15
years since three groups independently showed that ablation of the GDNF gene
(Gdnf –/– mice) results in animal death after birth due to renal agenesis and the
absence of then enteric plexus.69–71 Unexpectedly, the Gdnf –/– mice had an
apparently normal number and organization of mesencephalic DA neurons.
These observations suggested that the trophic dependence of nigrostriatal
neurons on GDNF, supported by the pharmacological experiments (exogenous
administration of the trophic factor), must be acquired during postnatal
maturation. Heterozygous Gdnf mice are fertile and develop normally,
although they manifest an accelerated decline in spontaneous motor activity
and coordination with age.72 Nevertheless, this embryonic GDNF deﬁcit seems
to have little impact on the adult, since at 20 months of age, the mice show only
a 15% decrease of TH-positive SN neurons and no diﬀerence in striatal TH1
ﬁbre density with respect to controls.72 Gdnf 1/– mice, however, seemed to show
a higher susceptibility to neurotoxin-induced long-term degeneration of
monoaminergic neurons than wild-type littermates.73
Figure 8.2 Transplantation of carotid body cell aggregates in rodent models of
Parkinson’s disease. (A) Histological section at the level of the mouse
striatum showing the expression of GDNF (green colour) in a carotid
body transplant from a GDNF/LacZ mouse (see ref. 71). (B) Histological
section of a striatum containing a carotid body transplant. Cells in
the graft show the expression of GDNF (green colour aggregasomes,
X-gal staining) in tyrosine hydroxylase (TH) positive glomus cells (brown
colour). (C) Rotational behavior of a hemiparkinsonian rat before (BT)
and after (AT) intrastriatal transplantation of carotid body tissue.
Modiﬁed from refs. 60,61.
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Region-speciﬁc genetic deletion (driven by the promoter of the dopamine
transporter gene) of Ret (the canonical GDNF receptor) in DA neurons has
provided conﬂicting results regarding the role of this pathway in the main-
tenance of adult neurons. No diﬀerences in adult DA nigrostriatal neurons
have been shown in Ret-null mice versus controls, as determined by com-
parative morphometric and biochemical analysis.31 However, another group
has reported that embryonic deletion of Ret in catecholaminergic neurons
results in a signiﬁcant decrease of TH1 SN neurons and striatal nerve terminals
of aged mice although, unexpectedly, neurons in the VTA and LC remain
unaﬀected.74 The variable results obtained with the regional Ret-null mouse
might be related to the fact that, besides the Grfa-1/Ret pathway, GDNF can
signal through ‘non canonical’ N-CAM receptors,32 that may compensate for
the absence of Ret.
We have recently reported the generation of a conditional GDNF-null mouse
in which GDNF expression was markedly reduced in adulthood.29 This model
avoids the establishment of developmental compensatory modiﬁcations, which
could mask the true physiologic action of GDNF in the adult nervous system.
The conditional GDNF deﬁcient mice show selective and extensive catecho-
laminergic neuronal death, most notably in the LC, SN and VTA (Figure 8.3).
GABAergic and cholinergic pathways appear to be unaﬀected. The neuro-
chemical and histological alterations in GDNF-deprived mice induce the
appearance of behavioural motor disturbances characterized by a progressive
akinetic syndrome (Figure 8.4). These data have demonstrated that endogenous
GDNF is absolutely required for trophic maintenance of mesencephalic
Figure 8.3 Mesencephalic catecholaminergic neuronal death in the adult conditional
GDNF knout out mouse. (A) Mesencephalic dopaminergic neurons in
substantia nigra (SN) and ventral tegmental area (VTA) on a conditional
GDNF-null animal before (TM) and seven months after (þTM) dele-
tion of the GDNF gene. (B) Same experiment showing the disappearance
of cells in the locus coeruleus (LC) after GDNF depletion. Modiﬁed
from ref. 29.
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Figure 8.4 Motor abnormalities in the adult conditional GDNF knock-out mouse par-
kinsonianmodel. Spontaneous activity (animals were recorded during 60min
in an open ﬁeld chamber)measured inwild-type (black bars:GDNF1/1; þ/þ
mice treated with TM; n¼ 13) and GDNF depleted animals (grey bars:
GDNFF/; Cre-Esr1 mice treated with TM; n¼ 7) three days before and 37,
60, 100, and 126 days after TM injection. (A) Four traces from wild-type and
GDNF-depleted animals are shown as representative of the time points 100
and 126 days after TM injection. Activity trace during minutes 16–30 is pre-
sented. (B) Travelled distance (cm) was calculated by following the centre of
gravity of the subject. (C) Resting time (s) was the time spent in resting state
(with reference to the default velocity threshold of 2.57 cm/s). (D,E) Vertical
movements quantiﬁed in three periods of ﬁve minutes from each animal and
time point. Averaged readings (D) and the accumulated time spent with both
forepaws without contacting the ﬂoor (E) are plotted. Each individual point
represents 3–8 animals. One-wayANOVA followed by the Tukey test.Means
 S.E.M.; *, po0.05; **, po0.01. Modiﬁed from ref. 29.
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dopaminergic and noradrenergic neurons. The GDNF-deﬁcient mouse is a
well-deﬁned model in which to study neuroprotection in experimental PD. It
remains to be investigated in the future which essential GDNF-controlled
targets are required for mammalian SN, VTA and LC neuronal survival.
8.4 Clinical Eﬀects of GDNF
The good results obtained in the preclinical studies on the neuroprotective role
of GDNF have stimulated the development of clinical studies designed to test
the therapeutic eﬀects of GDNF in advanced PD patients. Besides the clinical
studies with CB tissue referred to above, several clinical trials have been per-
formed using direct intracerebral infusion of GDNF.
In a controlled clinical trial, monthly intraventricular GDNF injection failed
to provide clinical beneﬁt in advanced PD patients and instead resulted in
frequent adverse events.75 A postmortem examination in one patient suggested
that GDNF did not reach the target cells via this route. However, encouraging
clinical and neurochemical results were observed with continuous intrapu-
taminal GDNF infusion on PD patients in two independent open-label clinical
trials. One of the trials performed on ﬁve PD patients reported encouraging
clinical outcomes at one year, while [18F]-dopa PET studies showed an increase
in putaminal uptake around the tip of each catheter.76 The second study on 10
patients using a diﬀerent delivery protocol also reported positive results at six
months.77 However, a randomized placebo-controlled trial involving 34 PD
patients showed no signiﬁcant clinical diﬀerences between groups at six months
despite increased [18F]-dopa uptake in the recombinant GDNF-treated
group.78 The open-label extension of this study was halted due to safety
concerns: three patients developed neutralizing antibodies, which could
potentially cross-react with endogenous GDNF, while in a parallel toxicology
study some monkeys developed cerebellar damage. Besides GDNF, other
members of the same protein family (particularly neurturin) are also being
assayed in pilot clinical trials with yet inconclusive results.
8.5 Conclusions and Perspectives
NTFs exert a potent eﬀect on the survival and maintenance of phenotype in
adult neurons. Therefore intracerebral administration of these factors is a
promising therapeutic strategy in neurodegenerative disorders, such as PD,
presenting progressive neuronal death. There is a vast scientiﬁc literature
supporting the neuroprotective role of exogenous GDNF on the nigrostriatal
pathway. However, most of the clinical trials performed to test the eﬃcacy of
NTF-based therapies in advanced PD patients have been quite discouraging.
The generation of the conditional GDNF-null mouse model has recently
allowed us to show the absolute requirement of GDNF for the survival
of dopaminergic and noradrenergic mesencephalic neurons in adult brain.
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These data unequivocally demonstrate a major physiological neuroprotective
eﬀect of GDNF and thus it should revive interest in GDNF-based therapies.
Clinical application of NTFs is confronted with several technological and
scientiﬁc challenges that should be addressed in future preclinical and clinical
research. Before new clinical trials are performed, a safe and eﬃcacious route of
GDNF delivery (produced in cells, puriﬁed, or encoded in viral vectors) must
be clearly established. In this regard, diﬀusion of GDNF in the brain
parenchyma and the appropriate concentration of GDNF delivered to cells are
critical issues that might determine the clinical outcome. It must be also
investigated whether the administration of appropriate cocktails of several
trophic factors oﬀer advantages over the use of GDNF alone. Besides these
technologically oriented studies, much research should be done to unravel the
actual physiological role of NTFs and their molecular mechanism of action on
adult neurons. This work might eventually lead to the identiﬁcation of new
signalling pathways that will provide targets accessible to small molecules
amenable for their use as pharmaceutical drugs. The molecular physiology and
pharmacology of neuroprotection are still in their infancy. Therefore, it can
be presumed that the development of these ﬁelds will surely oﬀer new oppor-
tunities for a more eﬀective ﬁght against PD and other neurodegenerative
diseases.
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